Adam K. Stern
Adam K. Stern is a New York based venture capitalist and private equity investment banker[1]. He is currently a Director of LabStyle Innovations (OTCBB: DRIO)[2], Matinas BioPharma Holdings[3], and is a past Director of Prolor Biotech (formerly NYSE MKT:PBTH)[4], InVivo Therapeutics (OTC Markets:NVIV)[5], and Organovo Holdings (NYSE MKT: ONVO)[6]. Mr. Stern is recognized in the life science community[7] [8] as having identified and provided the seed or early stage financing to disruptive ventures[9], among them the world's first 3-D bioprinter, a Time Magazine '50 Best Inventions of 2010'[10]. Mr. Stern has rung the New York Stock Exchange opening bell with both Organovo and Prolor Biotech[11] [12].
Prolor Biotech Inc. was acquired by Opko Health Inc. (OPK) in an all-stock deal valued at $480 million[13]. In addition to providing the seed financing for Prolor, Mr. Stern, as Chairman of the Special Committee, was charged by the PROLOR Board of Directors with the responsibility to, among other things, evaluate and negotiate its eventual acquisition[14]. Attaching Prolor Biotech's (formerly Modigene, Inc.) Carboxyl Terminal Peptide technology to therapeutic proteins is a FDA approved[15] non-immunogenic method to substantially increase protein longevity, increasing the time between doses.[16][17].
References
- ↑ Napodano, Jason. "Off to the Races with Seven Extraordinary Biotech and Medtech Companies". Streetwise Reports. George S. Mack of The Life Sciences Report. Retrieved 3 March 2014.
- ↑ "LabStyle Innovations Corp (DRIO.OB)". Reuters Online. Reuters. Retrieved 3 March 2014.
- ↑ Thomas, Jenene. "Matinas BioPharma Appoints Adam K. Stern to Board of Directors". Market Wire Online. MarketWire LP. Retrieved 3 March 2014.
- ↑ "Prolor Biotech November 1, 2012 8-K". EDGAR Database. Securities and Exchange Commission. Retrieved 3 March 2014.
- ↑ "InVivo Therapeutics Closes Oversubscribed Private Placement, Raising $13 Million" (PDF). Invivo Therapeutics Investor Relations. David Pitts. Retrieved 3 March 2014.
- ↑ "Organovo Insider: Adam Stern". MacroAxis Personalized Investing and Digital Wealth Creation. MacroAxis.com. Retrieved 3 March 2014.
- ↑ "Gen Calendar". Genengnews.com. Genetic Engineering & Biotech News. Retrieved 4 March 2014.
- ↑ Elliott, Mike. "Adam K. Stern: Board Member / InVivo's Board of Directors / Management Team". CEOLIVE.TV. Retrieved 4 March 2014.
- ↑ Baum, Stephanie. "Could Organovo's first commercial device, 3-D liver model for pharma, cut drug R&D costs? Read more: http://medcitynews.com/2013/11/organovo-test-drives-3-d-printed-liver-40-days-lab/#ixzz2uy8orSjx". Medcity News Online, What's Next in Medical Innovation. Medcity News. Retrieved 4 March 2014. External link in
|title=(help) - ↑ Kluger, Jeffrey. "The 50 Best Inventions of 2010". Time Magazine. Time, Inc. Retrieved 4 March 2014.
- ↑ "Organovo Celebrates Listing on NYSE MKT". NYSE Euronext. Retrieved 4 March 2014.
- ↑ "3 June 2010 PROLOR rings the NYSE Opening Bell". NYSE Euronext. Retrieved 4 March 2014.
- ↑ "Prolor Biotech Agrees to Be Acquired by Opko for $480 Million". Wall Street Journal Online, US Edition. Wall Street Journal. Retrieved 3 March 2014.
- ↑ "Prolor 424(b)(3), April 23, 2013". Edgar Online. Securities and Exchange Commission. Retrieved 4 March 2014.
- ↑ "Merck receives FDA approval for new fertility drug for women news". Domain-B.com. The Information Company Private Limited. Retrieved 4 March 2014.
- ↑ Macdonald, Gareth. "CTP is "best-of-breed" for enhancing protein longevity". in-Pharma Technologist. William Reed Business Media. Retrieved 4 March 2014.
- ↑ "PROLOR: The Added Value Of Reversible PEGYlation". Prohost Biotech Market Insight & Analysis. Prohost Biotech. Retrieved 4 March 2014.
This article "Adam K. Stern" is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
